In view of the high attrition rate of Aβ‐based anti‐AD drugs and the poor compliance of DME patients for anti‐VEGF biologics, Lp‐PLA2 inhibitors can yet be regarded as a potential good choice. The gene discussed is VEGFA; the disease is Alzheimer disease.